to BM plasma cell infiltration. Treatment with infusional vincristine and doxorubicin plus high dose methyl-prednisolone (VAMP protocol) was initiated, but no objective response was observed after three courses. Salvage treatment with myeloablative therapy and autologous stem cell support was thus considered. Due to marked BM plasma cell infiltration peripheral blood progenitor cells (PBPC) support was preferred.
PBPC collection
At the time of PBPC collection the peripheral blood (PB) smear showed 5% blasts and other immature myeloid cells, but no myeloma cells in the differential count. The PB immunophenotype in the steady state revealed a marked expansion of progenitor cells. CD34
+ cells constituted 2% of the WBC counts, equivalent to 2.4 × 10 5 CD34 + cells/ml 
CD34
+ ml, respectively), and the presence of 1.2% cells (1.44 × 10 5 /ml) with plasma cell cIg + , CD38 + phenotype. phatase were within normal limits. Coagulation tests and
Further analysis failed to reveal any atypical pattern in urine analysis were normal. Serum protein electrophoresis myeloid antigen expression in CD34 + cell subsets. PB cell revealed a 57 g/l ␥-globulin monoclonal band. Immunocultures showed increased CFU-GM (7.92 × 10 3 /ml), BFUglobulins were 2.5 g/l IgG, 0.5 g/l IgA, 0.3 g/l IgM and E (9.34 × 10 3 /ml), CFU-E (3.44 × 10 4 /ml), and CFU-MK 53 g/l IgD paraprotein. Bence-Jones proteinuria was (5.86 × 10 4 /ml). Since previous BM cytogenetics could not negative. Serum ␤-2 microglobulin was increased to be representative for myeloid cell lines as a result of heavy 12.3 mg/l (normal Ͻ2.5 mg/l). C-reactive protein (CRP) plasma cell infiltration, we repeated the cytogenetic study was increased to 4.6 mg/dl (normal Ͻ0.75 mg/dl). X-ray with PB cells showing a 46 XXq+ karyotype. These prebone survey showed diffuse osteopenia without lytic bone liminary tests suggested that the PBPC expansion was polylesions. Abdominal ultrasonography showed homogeneous clonal in nature and that the circulating progenitor cells hepatomegaly and 19 cm diameter splenomegaly. Bone could be used to support a course of myelo-ablative thermarrow (BM) examination showed infiltration by Ͼ80% apy. We also evaluated the resistance of PBPC to cryoatypical plasma cells. The myeloid and erythroid cells were preservation and thawing, obtaining a 65% recovery of proportionately reduced and very few megakaryocytes CFU-GM. Then, PBPC were directly collected at steady could be seen. BM core biopsy showed a diffuse plasma state by leukopheresis using a Fresenius cell processor cell infiltration that mostly replaced hematopoiesis (Fresenius, Wendel, Germany). On 2 consecutive days, (Figure 1 ). With appropriate stains, BM reticulin fibrosis 1.9 × 10 8 /kg mononuclear cells, 7.72 × 10 6 /kg CD34 + cells was patent ( Figure 2 ). The BM cytogenetic study disclosed and 8.87 × 10 4 /kg CFU-GM were obtained and cryoprea normal 46 XY karyotype. A diagnosis of high tumor burserved in two fractions. den IgD-myeloma was made. Organomegaly, leukoerythroblastosis and marrow fibrosis were considered reactive
Autologous transplantation and course
Melphalan (200 mg/m 2 ) was administered, and subsequently one PBPC fraction with 5.24 × 10 6 /kg CD34 + cells was reinfused. G-CSF (10 g/kg/day) was given until WBC recovery. Engraftment was rapid, requiring 7 days for Ͼ0.5 × 10 9 /l granulocytes and 14 days for Ͼ20 × 10 9 /l platelets. Of note was a rapid decline in spleen size and the monoclonal serum spike. Acute regimen-related toxicity was not severe and the patient was discharged 20 days after PBPC infusion. However, on day 38 he was readmitted with fever and bilateral lung infiltrates. Bronchoalveolar lavage rapid culture revealed cytomegalovirus infection and therapy with ganciclovir and high-dose immunoglobulin resolved the picture. When the patient was evaluated 6 months after autotransplantation no spleen enlargement was felt, blood counts and differential counts were normal and a major disease response was apparent, with no IgD M spike in serum protein electrophoresis and normal IgG, IgA and IgM values. Furthermore, the BM was normocellular with plasma cell infiltration reduced to Ͻ3% and absence of reticulin fibrosis. We went on to a second myeloablative failure, 11 and can be used to select different strategies for stem cell procurement. Consequently, CD34
+ measurecourse with cyclophosphamide-BCNU-etoposide conditioning, supported with the second PBPC cryopreserved fracments are generally performed in patients scheduled for high-dose therapy who meet risk factors for mobilization tion (2.48 × 10 6 /kg CD34 + cells). No major toxicity was recorded and granulocyte and platelet counts recovered in failure. This patient was evaluated before stem cell procurement and autologous transplantation, when the leukoery-9 and 12 days, respectively. Normal blood cell counts were reached at 6 weeks and normal hematopoiesis maintained throblastic picture was prominent. We found a nearly 1000-fold increase in PBPC at steady state, measured both by until 7 months later, when progressive poor performance status and increasing serum IgD spike indicated a relapse phenotypical CD34 + typing and CFU-GM culture assay. Previous studies on increased levels of PBPC are very limof myeloma. Disease progression was again accompanied by splenomegaly, anemia, thrombocytopenia and leukoited and published series showed a 40-fold increase in CFU-GM and a much higher increase in CFU-MK in erythroblastosis. He received palliative therapy, but did not respond and died due to massive gastrointestinal bleeding.
patients with agnogenic myeloid metaplasia. However, cases with secondary myelofibrosis had less than a threefold increase in CFU-GM. 2, 3 The magnitude of PBPC expansion in this patient clearly exceeded the range of cirDiscussion culating PBPC previously described for myeloproliferative disorders, and has not been reported as a consequence of Bone marrow fibrosis has been reported to occur in nearly 10% of myeloma patients, 4 but coexistence of myeloma secondary bone marrow fibrosis. The absence of a major cytogenetic aberration and a normal profile of myeloid difwith a clinical syndrome mimicking agnogenic myeloid metaplasia with splenomegaly, leukoerythroblastosis and ferentiation antigens in the CD34 + subset of cells, suggested that the PBPC pool was not conditioned by a clonal disease red cell poikilocytosis is very unusual and only occasional cases have been published. Previous case reports focused and could have a role in the support of myeloablative therapy. However, due to concern about reduced hematopoietic on whether a simultaneous myeloproliferative disorder was present, but most evidence suggested that myelofibrosis activity, the PBPC fraction reinfused after the first myeloablative course exceeded twice the minimum cell dose was a myeloma-related feature, since clinical remission of the plasma cell dyscrasia induced by chemotherapy was folusually required to ensure engraftment. The engraftment kinetics were rapid, with almost identical times to granulolowed by resolution of the fibrosis. 5, 6 The clinical course of the case presented here also sugcyte and platelet recovery to those recorded in other patients with PBPC collected after priming with chemogested that myelofibrosis was directly related to the proliferation of atypical plasma cells rather than to a coexisting therapy or growth factors. We verified the hematopoietic potential of the expanded PBPC pool in this patient at the primary myeloproliferative disorder. Bone marrow megakaryocyte hyperplasia and PB red cell poikilocytosis, which second myeloablative course. The PBPC fraction, with a cell content close to the minimum, also produced a rapid are characteristic features of agnogenic myeloid metaplasia, were absent in this patient. Furthermore, bone marrow and sustained hematopoietic reconstitution lasting until the relapse of myeloma. Hematopoiesis after this second autofibrosis and other related clinical manifestations always followed the course of the myeloma, as they resolved when logous transplantation was normal and apparently polyclonal, dissipating any concerns for a possible expression high-dose therapy induced a complete remission of the disease and reappeared on myeloma progression. An alternaof a myeloproliferative disorder. Splenomegaly, leukoerythroblastosis and bone marrow failure were only noted at tive hypothesis could be a cytokine-mediated mechanism induced by the neoplastic plasma cells, causing collagen the time of myeloma progression. It is generally considered that IgD myeloma has a worse deposition in BM connective tissue. We found high CRP serum levels in this patient and although we could not perprognosis than other types of myeloma, but recent analysis has shown that response to therapy is similar to other myeform a thorough evaluation of cytokines in serum or bone marrow, high CRP has been related to IL-6 overproduction loma types. 12 High-dose melphalan induced in this patient a rapid decline in the serum IgD component, an impressive and poor prognosis in myeloma. 7 Other unknown cytokines produced as a result of plasma cell proliferation could be reduction in the spleen size and normalization in PB cell counts shortly after transplantation, and at 6 months a commediating myelofibrosis in this case.
Another outstanding feature in this case was the marked plete remission was achieved with disappearance of myelofibrosis. Since double transplants may improve the diseasebaseline expansion of the PBPC pool. In recent years, accumulated experience with PBPC processing has free survival in myeloma, mainly when a second transplant is done after a complete remission achieved with one initial revealed that mobilization and post-transplant hematopoietic recovery may be impaired in some patients. This has myeloablative course, 13 a second myeloablative course was given with the intention of reducing the risk of disease been mostly attributed to damage to the hematopoietic reserve damage as a result of previous treatment with relapse, but remission duration was only 13 months. Whether we could have improved the long-term result with alkylating agents, but also to the patient's advanced age or high tumor burden at the time of PBPC collection. 
